1 Min Read
March 23 (Reuters) - Sigma Pharmaceuticals Ltd:
* FY underlying npat up 13.0% to $66.9 million
* "we confirm our previous guidance of at least 5pct underlying ebit growth for fy18"
* FY revenue $4.4 billion, up 26.2pct
* Proposed final dividend of 3.0 cents per share Source text for Eikon: Further company coverage: